[1] AURILIO G,CIMADAMORE A,MAZZUCCHELLI R,et al.Androgen receptor signaling pathway in prostate cancer:from genetics to clinical applications[J].Cells,2020,9(12):2653.
[2] MERSEBURGER A S,ALCARAZ A,VON KLOT C A.Androgen deprivation therapy as backbone therapy in the management of prostate cancer[J].Onco Targets Ther,2016,9:7263-7274.
[3] NIU Y,GUO C,WEN S,et al.ADT with antiandrogens in prostate cancer induces adverse effect of increasing resistance,neuroendocrine differentiation and tumor metastasis[J].Cancer Lett,2018,439:47-55.
[4] SAGNAK L,TOPALOGLU H,OZOK U,et al.Prognostic significance of neuroendocrine differentiation in prostate adenocarcinoma[J].Clin Genitourin Cancer,2011,9(2):73-80.
[5] CHEN R,DONG X,GLEAVE M.Molecular model for neuroendocrine prostate cancer progression[J].BJU Int,2018,122(4):560-570.
[6] YAMADA Y,BELTRAN H.Clinical and biological features of neuroendocrine prostate cancer[J].Curr Oncol Rep,2021,23(2):15.
[7] MEHRAJ U,GANAI R A,MACHA M A,et al.The tumor microenvironment as driver of stemness and therapeutic resistance in breast cancer:New challenges and therapeutic opportunities[J].Cell Oncol (Dordr),2021,44(6):1209-1229.
[8] ZHOU H,HE Q,LI C,et al.Focus on the tumor microenvironment:A seedbed for neuroendocrine prostate cancer[J].Front Cell Dev Biol,2022,10:955669.
[9] LIU Q,YU S,LI A,et al.Targeting interlukin-6 to relieve immunosuppression in tumor microenvironment[J].Tumour Biol,2017,39(6):1010428317712445.
[10] NATANI S,DHOPLE V M,PARVEEN A,et al.AMPK/SIRT1 signaling through p38MAPK mediates Interleukin-6 induced neuroendocrine differentiation of LNCaP prostate cancer cells[J].Biochim Biophys Acta Mol Cell Res,2021,1868(10):119085.
[11] YU S H,MAYNARD J P,VAGHASIA A M,et al.A role for paracrine interleukin-6 signaling in the tumor microenvironment in prostate tumor growth[J].Prostate,2019,79(2):215-222.
[12] JI Y,LIU B,CHEN L,et al.Repurposing ketotifen as a therapeutic strategy for neuroendocrine prostate cancer by targeting the IL-6/STAT3 pathway[J].Cell Oncol (Dordr),2023,46(5):1445-1456.
[13] ZHU Y,LIU C,CUI Y,et al.Interleukin-6 induces neuroendocrine differentiation (NED) through suppression of RE-1 silencing transcription factor (REST)[J].Prostate,2014,74(11):1086-1094.
[14] CHANG P C,WANG T Y,CHANG Y T,et al.Autophagy pathway is required for IL-6 induced neuroendocrine differentiation and chemoresistance of prostate cancer LNCaP cells[J].PLoS One,2014,9(2):e88556.
[15] LEHRER S,DIAMOND E J,MAMKINE B,et al.Serum interleukin-8 is elevated in men with prostate cancer and bone metastases[J].Technol Cancer Res Treat,2004,3(5):411.
[16] PATEL B J,PANTUCK A J,ZISMAN A,et al.CL1-GFP:an androgen independent metastatic tumor model for prostate cancer[J].J Urol,2000,164(4):1420-1425.
[17] LEE L F,LOUIE M C,DESAI S J,et al.Interleukin-8 confers androgen-independent growth and migration of LNCaP:differential effects of tyrosine kinases Src and FAK[J].Oncogene,2004,23(12):2197-2205.
[18] HUANG J,YAO J L,ZHANG L,et al.Differential expression of interleukin-8 and its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate cancer[J].Am J Pathol,2005,166(6):1807-1815.
[19] LI Z,CHEN C J,WANG J K,et al.Neuroendocrine differentiation of prostate cancer[J].Asian J Androl,2013,15(3):328-332.
[20] ZHANG X Q,KONDRIKOV D,YUAN T C,et al.Receptor protein tyrosine phosphatase alpha signaling is involved in androgen depletion-induced neuroendocrine differentiation of androgen-sensitive LNCaP human prostate cancer cells[J].Oncogene,2003,22(43):6704-6716.
[21] KIM J,JIN H,ZHAO J C,et al.FOXA1 inhibits prostate cancer neuroendocrine differentiation[J].Oncogene,2017,36(28):4072-4080.
[22] DI LORENZO G,TORTORA G,D'ARMIENTO F P,et al.Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer[J].Clin Cancer Res,2002,8(11):3438-3444.
[23] LI Y,CHEN H Q,CHEN M F,et al.Neuroendocrine differentiation is involved in chemoresistance induced by EGF in prostate cancer cells[J].Life Sci,2009,84(25-26):882-887.
[24] CORTÉS M A,CARIAGA-MARTINEZ A E,LOBO M V,et al.EGF promotes neuroendocrine-like differentiation of prostate cancer cells in the presence of LY294002 through increased ErbB2 expression independent of the phosphatidylinositol 3-kinase-AKT pathway[J].Carcinogenesis,2012,33(6):1169-1177.
[25] ZHANG Y,ZHAO J,DING M,et al.Loss of exosomal miR-146a-5p from cancer-associated fibroblasts after androgen deprivation therapy contributes to prostate cancer metastasis[J].J Exp Clin Cancer Res,2020,39(1):282.
[26] PRUD'HOMME G J,KURT M,WANG Q.Pathobiology of the klotho antiaging protein and therapeutic considerations[J].Front Aging,2022,3:931331.
[27] XU X,ZHENG L,YUAN Q,et al.Transforming growth factor-β in stem cells and tissue homeostasis[J].Bone Res,2018,6:2.
[28] DICKEN H,HENSLEY P J,KYPRIANOU N.Prostate tumor neuroendocrine differentiation via EMT:the road less traveled[J].Asian J Urol,2019,6(1):82-90.
[29] NATANI S,SRUTHI K K,ASHA S M,et al.Activation of TGF-β-SMAD2 signaling by IL-6 drives neuroendocrine differentiation of prostate cancer through p38MAPK[J].Cell Signal,2022,91:110240.
[30] PLATZ E A,DE MARZO A M.Epidemiology of inflammation and prostate cancer[J].J Urol,2004,171(2 Pt 2):S36-S40.
[31] UNTERGASSER G,PLAS E,PFISTER G,et al.Interferon-gamma induces neuroendocrine-like differentiation of human prostate basal-epithelial cells[J].Prostate,2005,64(4):419-429.
[32] BORKOWETZ A,FROEHNER M,RAUNER M,et al.Neuropilin-2 is an independent prognostic factor for shorter cancer-specific survival in patients with acinar adenocarcinoma of the prostate[J].Int J Cancer,2020,146(9):2619-2627.
[33] ISLAM R,MISHRA J,POLAVARAM N S,et al.Neuropilin-2 axis in regulating secretory phenotype of neuroendocrine-like prostate cancer cells and its implication in therapy resistance[J].Cell Rep,2022,40(3):111097.
[34] WANG J,LI J,YIN L,et al.Neuropilin-2 promotes lineage plasticity and progression to neuroendocrine prostate cancer[J].Oncogene,2022,41(37):4307-4317.
[35] WANG M,WISNIEWSKI C A,XIONG C,et al.Therapeutic blocking of VEGF binding to neuropilin-2 diminishes PD-L1 expression to activate antitumor immunity in prostate cancer[J].Sci Transl Med,2023,15(694):eade5855. |
